Minerva Surgical, Inc. is a medical technology company. The company is headquartered in Santa Clara, California and currently employs 174 full-time employees. The company went IPO on 2021-10-22. The firm designs, manufactures, distributes, and commercializes a suite of products that offer effective alternatives to hysterectomy, with a focus on diagnosing and treating the underlying causes of Abnormal Uterine Bleeding (AUB). Its solutions are designed for use across a variety of care settings and focused on improving clinical outcomes and preserve uterine anatomy. The company delivers devices that treat the root causes of AUB in both the normal and irregular shaped uterus. The firm's products include Minerva ES Endometrial Ablation System (Minerva ES), Genesys HTA Endometrial Ablation System (Genesys HTA), Symphion Operative Hysteroscopy System (Symphion), Resectr Tissue Resection Device (Resectr), and HERizon Disposable Hysteroscope. Its Minerva EAS includes PlasmaSense Technology, which monitors uterine cavity. The company also provides HERizon Hysto-Kit, which supports in-office hysteroscopy.
Minerva Surgical Inc'in temel mali tabloları nelerdir?
Son mali tabloya (Form-10K) göre, Minerva Surgical Inc'in toplam varlıkları $0 olup, net 損失 $0'dir.
UTRS'ün temel finansal oranları nelerdir?
Minerva Surgical Inc'in cari oranı 0, net kâr marjı 0, hisse başına satış $0'dir.
Minerva Surgical Inc'in geliri segment veya coğrafya bazında nasıl dağılıyor?
Minerva Surgical Inc の最大収益セグメントは Research and Development で、最新の利益発表における収益は 1,172,000 です。地域別に見ると、United States が Minerva Surgical Inc の主要市場であり、収益は 1,172,000 です。
Minerva Surgical Inc kârlı mı?
いいえ, son mali tablolara göre Minerva Surgical Inc'in net 損失 $0'dir.
Minerva Surgical Inc'in herhangi bir yükümlülüğü var mı?
いいえ, Minerva Surgical Inc'in yükümlülüğü 0'dir.
Minerva Surgical Inc'in tedavüldeki hisse sayısı kaçtır?
Minerva Surgical Inc'in toplam tedavüldeki hisse sayısı 0'dir.